Skip to main content

Table 3 Characteristics of patients in the groups with high ΔCRP/Alb ratio (≧ 0.077) and the group with low Δ CRP/Alb ratio (< 0.077)

From: Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer

 

High Δ CRP/Alb group (n = 13)

Low Δ CRP/Alb group (n = 36)

p value

Age (years)

74

68

0.1663

Sex: female

6 (46.2)

16 (44.4)

0.916

Tumor size (mm)

30

20

0.076

<Pre-NACRT>

 CEA (ng/mL)

5.5

3.9

0.1235

 CA19-9 (U/mL)

537

214

0.1889

 FDG-PET (SUVmax)

7.8

7.0

0.5926

 Resectability: BR

2 (15.4)

6 (16.7)

0.9155

 BMI

23.5

22.1

0.1129

 CRP (mg/dL)

0.41

0.16

0.0698

 Alb (g/dL)

3.8

3.9

0.7941

 NLR

2.51

2.00

0.0852

 GPS 2 or 1

4 (30.8)

10 (27.8)

0.8395

 mGPS 2 or 1

2 (15.4)

3 (8.3)

0.4761

<Post-NACRT>

 CEA (ng/mL)

6.5

3.5

0.1333

 CA19-9 (U/mL)

455

107

0.0728

 Î”Weight loss (kg)

1.55

0.48

0.0314

 CRP (mg/dL)

1.32

0.08

< 0.0001

 Alb (g/dL)

3.2

3.9

0.0015

 NLR

3.20

3.34

0.9639

 GPS 2 or 1

11 (84.6)

10 (27.8)

0.0004

 mGPS 2 or 1

10 (76.9)

0 (0)

< 0.0001

<Perioperative and postoperative factor>

 Intraoperative bleeding (mL)

1764

1005

0.0666

 Complication after surgerya

2 (15.4)

10 (27.8)

0.3780

 Postoperative hospital stays (days)

29

25

0.5183

 T3

2 (15.4)

5 (13.9)

0.8960

 N2 or N1

7 (53.8)

18 (50.0)

0.8139

 PVI

5 (38.5)

10 (27.8)

0.4783

 Surgical margin: R1

4 (30.8)

10 (27.8)

0.8395

 Evans I or IIa

11 (84.6)

22 (61.1)

0.1252

 Uncompleted adjuvant chemotherapy

7 (53.9)

15 (41.7)

0.4539

  1. Data are median or n (%)
  2. CRP, C-reactive protein; Alb, albumin; NACRT, neoadjuvant chemoradiotherapy; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; FDG-PET, fluorodeoxyglucose positron emission tomography; SUVmax, maximum standardized uptake value; borderline resectable; BMI, body mass index; NLR, neutrophil/lymphocyte ratio; GPS, Glasgow Prognostic Score; mGPS, modified Glasgow Prognostic Score; PVI, portal vein invasion
  3. aComplication after surgery: Clavien-Dindo ≧ IIIa